US › Healthcare

Cue Biopharma (CUE)

US · Healthcare · Biotechnology

$37.84+10.74%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$7.9M

Revenue YoY

+166.7%

Net profit

$-153.1M

EPS

$-13.81

EPS estimate

$-1.69

Net margin

-1,943.2%

EPS came in at -13.81 against a street estimate of -1.69 — a miss of 717.2%.

Key statistics

Market cap

$208.8M

Forward P/E

0.0

P/B

90.63

Book value

$0.44

EPS (TTM)

$-29.46

52-week high

$45.50

52-week low

$4.97

50-day MA

$29.30

200-day MA

$19.06

Beta

2.46

Analyst view

Analysts rate Cue Biopharma a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $90.50.

Shareholding

Insiders

9.44%

Institutions

22.63%

Largest institutional holders

Fund	Stake
Bleichroeder LP	3.13%
Polygon Management Ltd	1.29%
Vanguard Capital Management, LLC	1.13%
Lion Point Capital, LP	0.73%
Squadron Capital Management LLC	0.69%
Diadema Partners LP	0.67%
Geode Capital Management, LLC	0.49%
Vanguard Fiduciary Trust Co	0.25%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Cue Biopharma — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.